Related references
Note: Only part of the references are listed.Model-based angiogenic inhibition of tumor growth using modern robust control method
Levente Kovacs et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2014)
Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer
Joshua McCarroll et al.
Frontiers in Physiology (2014)
The artificial pancreas: a digital-age treatment for diabetes
Claudio Cobelli et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Evidence-based role of bevacizumab in non-small cell lung cancer
E. E. Vokes et al.
ANNALS OF ONCOLOGY (2013)
Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer
J. -C. Soria et al.
ANNALS OF ONCOLOGY (2013)
The Impact of Bevacizumab (Avastin) on Survival in Metastatic Solid Tumors - A Meta-Analysis and Systematic Review
Limor Amit et al.
PLOS ONE (2013)
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
H. J. Schmoll et al.
ANNALS OF ONCOLOGY (2012)
BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma
Kevin B. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401
William Kevin Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Avastin loses breast cancer indication
Karen Carey
NATURE BIOTECHNOLOGY (2012)
Fighting Fire with Fire: Rekindling the Bevacizumab Debate
Alberto J. Montero et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
Harry D. Bear et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
Gunter von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Vascular Normalization as a Therapeutic Strategy for Malignant and Nonmalignant Disease
Shom Goel et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)
Induced L2-norm minimization of glucose-insulin system for Type I diabetic patients
Levente Kovacs et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2011)
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Atsushi Ohtsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Bevacizumab (Avastin)
S. K. Mukherji
AMERICAN JOURNAL OF NEURORADIOLOGY (2010)
Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
Niall C. Tebbutt et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Hedy Lee Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Antiangiogenic drugs in ovarian cancer
G. C. Kumaran et al.
BRITISH JOURNAL OF CANCER (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study
Bradley J. Monk et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Bevacizumab (Avastin) does not harm retinal function after intravitreal injection as shown by electroretinography in adult mice
Peter Heiduschka et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2008)
Drug Insight: antiangiogenic therapies for gastrointestinal cancers - focus on monoclonal antibodies
Anke Reinacher-Schick et al.
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY (2008)
Effect of vascular normalization, by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: Insights from a mathematical model
Rakesh K. Jain et al.
CANCER RESEARCH (2007)
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Tracy T. Batchelor et al.
CANCER CELL (2007)
Antiangiogenic effect of low-dose cyclophosphamide combined with ginsenoside Rg3 on Lewis lung carcinoma
QY Zhang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors
RT Tong et al.
CANCER RESEARCH (2004)
Share Paper
